News & Perspective

Nov 20, 2006

Nov 20, 2006

HHS awards 3 contracts for more H5N1 vaccine

(CIDRAP News) – The US government today announced the awarding of three contacts to buy enough additional H5N1 avian influenza vaccine to immunize almost 2.7 million people, at a cost of $199.45 million.

Nov 02, 2006

Nov 02, 2006

WHO report calls H5N1 vaccine stockpiling premature

(CIDRAP News) – A group of influenza experts convened by the World Health Organization cautioned today that governments shouldn't stockpile "pre-pandemic" H5N1 influenza vaccines now, because too little is known about the requirements for an effective vaccine.

Oct 17, 2006

Oct 17, 2006

Baxter says cell-based H5N1 vaccine shows potential in trial

(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.

Oct 13, 2006

Oct 13, 2006

Study supports concept of 2-stage H5N1 vaccination

(CIDRAP News) – The human immune system may respond better to a vaccine for a new strain of H5N1 avian influenza if it is prepared in advance with a vaccine based on an existing H5N1 strain, the preliminary results of a government-sponsored study suggest.

Sep 13, 2006

Sep 13, 2006

Live H5N1 vaccines show potential in animal study

(CIDRAP News) – Live-virus vaccines made from a combination of H5N1 avian influenza virus and another flu strain protected laboratory mice and ferrets from deadly infection with several different H5N1 strains, according to a report published yesterday.

Sep 07, 2006

Sep 07, 2006

Chinese report results for whole-virus H5N1 vaccine

Sept 7, 2006 (CIDRAP News) – In a human trial in China, a whole-virus H5N1 avian influenza vaccine generated an immune response with a relatively low dose of antigen, suggesting that it could be used to immunize more people than may be possible with some other vaccines under development.

Jul 26, 2006

Jul 26, 2006

Glaxo says its H5N1 vaccine works at low dose

(CIDRAP News) – An H5N1 avian influenza vaccine made by GlaxoSmithKline (GSK) triggered a good immune response in human volunteers at a much lower dose than other H5N1 vaccines reported so far, which means that hundreds of millions of doses could be produced by next year, the company announced today.

May 12, 2006

May 12, 2006

Sanofi reports results for H5N1 vaccine with adjuvant

(CIDRAP news) – In a human trial in France, an experimental H5N1 avian influenza vaccine with an adjuvant showed modestly better performance at a lower dose compared with a similar H5N1 vaccine that was tested earlier in the United States.

Mar 15, 2006

Mar 15, 2006

Leavitt vows action on flu vaccine technology

(CIDRAP News) – Health and Human Services (HHS) Secretary Mike Leavitt, reporting this week on preparations for a possible influenza pandemic, promised to act soon to boost US flu vaccine production capacity and promote cell-based vaccine technology.

Mar 07, 2006

Mar 07, 2006

HHS using Indonesian strain for second H5N1 flu vaccine

(CIDRAP News) – A second vaccine against human H5N1 influenza is being developed, US Health and Human Services (HHS) Secretary Mike Leavitt announced yesterday.

In a speech at an immunization conference, Leavitt announced that he has authorized the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to start work on a second vaccine, according to an Associated Press (AP) report published yesterday.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»